IGFBP2 and breast carcinoma: Using the MCF-7 breast cancer cell line, Martin et al. showed that inhibition of the PI3K signaling pathway using LY294002 or the mammalian target of rapamycin inhibitor rapamycin, IGFBP2 was markedly reduced; conversely, activation of PI3K signaling increased IGFBP2 levels25.